The search for genetic and environmental factors that may interact with the processes of advancing age to increase the incidence of Alzheimer's disease (AD) is an ongoing effort in many laboratories. Most of the efforts in discovering genetic factors associated with AD are centered on the nuclear genome. Yet, many studies have shown that mitochondrial structure and function change with both advancing age and, especially, with the onset and progression of AD. Investigators at the University of Kansas (KU) have been investigating the effects of cardiorespiratory fitness on AD progression and on the genetic and biochemical changes in brain mitochondria during the aging process and in AD. This combination of expertise and interests has led us to this proposed Core G, the Mitochondrial Genomics and Metabolism (MGM) Core. The goal of the MGM Core is to provide resources and expertise to investigators at KU and at other research institutions that will support studies on platelet, brain and muscle mitochondria obtained from well-characterized cases of AD, mild cognitive impairment (MCI), and age-matched controls. The scientific focus of the MGM Core is based on the idea that mitochondria play an important role in the pathogenesis of AD, both familial and late onset AD. The generation of reactive oxygen species in mitochondria, especially mitochondria with defective metabolism such as those in AD, can lead to oxidative modification of mtDNA, increases in the frequency of mutations in mtDNA, and mitochondrial dysfunction in terms of oxidative phosphorylation The Specific Aims of the MGM Core are: 1) Prepare, catalog, and store mitochondria, protein extracts, DNA, and RNA from living and deceased subjects recruited by the Clinical Core;2) Prepare and bank cybrid lines using neuronal cells and platelet mitochondria from living subjects;3) Perform limited mitochondrial DNA (mtDNA) sequence analysis and measurements of 8-OH-2-dG in order to jump-start larger, independently funded research into AD mtDNA gene structure and expression;and 4) Develop mitochondria- and metabolism-oriented AD research in the Kansas City region and assist in national AD research efforts focused on mitochondria.

Public Health Relevance

The genetic factors that lead to the Alzheimer's disease state are still not fully defined. Mitochondrial abnormalities in structure and function may be a common mechanism underlying the appearance and progression of AD. Investigation of mitochondrial function is one of the main avenues of future research that will be conducted by investigators at the University of Kansas and other institutions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG035982-04
Application #
8690727
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Cirstea, Carmen M; Lee, Phil; Craciunas, Sorin C et al. (2018) Pre-therapy Neural State of Bilateral Motor and Premotor Cortices Predicts Therapy Gain After Subcortical Stroke: A Pilot Study. Am J Phys Med Rehabil 97:23-33
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Morris, Jill K; Piccolo, Brian D; Shankar, Kartik et al. (2018) The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease. Am J Physiol Endocrinol Metab 314:E584-E596
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104

Showing the most recent 10 out of 333 publications